Hsbc Holdings PLC Insmed Inc Transaction History

Hsbc Holdings PLC

$176 Billion
Q3 2025

A detailed history of Hsbc Holdings PLC transactions in Insmed Inc stock. As of the latest transaction made, Hsbc Holdings PLC holds 1,512 shares of INSM stock, worth $292,148. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,512

Previous 12,949 88.32%

Holding current value

$292,148

Previous $1.3 Million 83.35%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$96.14 - $147.2 $1.1 Million - $1.68 Million	-11,437 Reduced 88.32%	1,512 $217,000
Q2 2025 Aug 13, 2025	SELL	$64.81 - $105.9 $549,199 - $897,396	-8,474 Reduced 39.56%	12,949 $1.3 Million
Q1 2025 May 14, 2025	BUY	$65.25 - $83.83 $20,553 - $26,406	315 Added 1.49%	21,423 $1.63 Million
Q4 2024 Feb 14, 2025	BUY	$66.29 - $76.63 $538,407 - $622,388	8,122 Added 62.54%	21,108 $1.46 Million
Q3 2024 Nov 14, 2024	SELL	$62.0 - $79.01 $630,230 - $803,136	-10,165 Reduced 43.91%	12,986 $947,000

Q2 2024 Aug 12, 2024	BUY	$22.0 - $69.71 $159,610 - $505,746	7,255 Added 45.64%	23,151 $1.55 Million
Q1 2024 May 15, 2024	BUY	$25.72 - $29.94 $408,845 - $475,926	15,896 New	15,896 $431,000
Q1 2021 May 14, 2021	SELL	$32.28 - $44.3 $304,142 - $417,394	-9,422 Closed	0 $0
Q4 2020 Feb 25, 2021	BUY	$31.45 - $40.54 $296,321 - $381,967	9,422 New	9,422 $313,000
Q1 2020 May 15, 2020	SELL	$13.63 - $33.98 $179,398 - $447,244	-13,162 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$16.12 - $24.98 $125,445 - $194,394	-7,782 Reduced 37.16%	13,162 $313,000
Q3 2019 Nov 14, 2019	BUY	$15.49 - $25.78 $324,422 - $539,936	20,944 New	20,944 $369,000

Others Institutions Holding INSM

# of Institutions

654

Shares Held

208M

Call Options Held

3.83M

Put Options Held

4.26M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $26.2B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account

Hsbc Holdings PLC Insmed Inc Transaction History